Actively Recruiting
International Study of Coronary Microvascular Angina iCorMicA a Randomised, Controlled, Multicentre Trial and Registry
Led by NHS Greater Glasgow and Clyde · Updated on 2026-04-09
1500
Participants Needed
39
Research Sites
235 weeks
Total Duration
On this page
Sponsors
N
NHS Greater Glasgow and Clyde
Lead Sponsor
U
University of Glasgow
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research investigates whether personalized medical treatment guided by a special diagnostic procedure during invasive coronary angiography can improve symptoms, wellbeing, cardiovascular risk, and clinical outcomes in patients with angina but no significant blockage in their coronary arteries. It focuses on patients with ischaemic heart disease, particularly those with angina without obstructive coronary artery disease INOCA, a condition affecting the small vessels of the heart. The trial builds on earlier pilot studies that suggested this approach could improve quality of life and symptom control by tailoring diagnosis and treatment more precisely. Participants undergo functional coronary angiography with a guidewire-based interventional diagnostic procedure IDP that measures coronary vascular function to classify patients into specific diagnosis groups, such as microvascular or vasospastic angina. Eligible patients are randomized into two groups one where IDP results are disclosed to clinicians to guide treatment, and another where IDP is performed but results are hidden, with care based on standard angiography and clinical information. Both groups receive medical therapy and lifestyle advice based on their diagnosis. The study also includes a registry for patients with obstructive disease who are not randomized. During the study, participants complete symptom questionnaires like the Seattle Angina Questionnaire to assess their angina symptoms and quality of life over at least 12 months. Researchers monitor health status, clinical outcomes, safety, and health economics, with ongoing follow-up planned for up to 10 years. Both patients and their usual care clinicians are blinded to the group allocation, but informed about the diagnosis to guide treatment. The trial aims to enroll 1500 participants across multiple centers in Europe, assessing the feasibility and impact of this stratified medicine approach.
CONDITIONS
Brief Title
iCorMicA - Stratified Medicine in Angina
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Planned clinical invasive coronary angiography
- Symptoms of angina (typical or atypical) based on Rose and/or Seattle Angina questionnaires
- Ability to comply with study procedures
- Able to give informed consent
You will not qualify if you...
- Non-coronary primary reason for invasive angiography (e.g., valve disease or heart failure)
- History of coronary artery bypass surgery
- Presence of obstructive coronary artery disease (stenosis >50% in a main artery >2.5 mm or fractional flow reserve 60.80)
- Logistical reasons preventing participation (patients with these enter a follow-up registry)
Research Team
C
Colin Berry, MBChB, PhD
D
Daniel Ang, MBChB
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here